Fujifilm and Predictive Oncology announce collaboration to make a significant impact on drug safety
A new solution exists for biopharmaceutical companies looking to enable the more accurate detection of residual endotoxins associated with biologic drug products. Together FUJIFILM Wako Chemicals U.S.A. Corporation (FUJIFILM), a supplier of high purity chemicals and reagents, and Predictive Oncology Inc., (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, are collaborating to reduce protein interference in bacterial endotoxin testing of biopharmaceutical products.
Predictive Oncology offers its validated sample treatment technology, EndoPrep™, to prevent interference of the biologic product with endotoxin detection. Combined with Fujifilm’s PYROSTAR™ bacterial endotoxin detection product, which is engineered to prevent glucan interference, biopharmaceutical manufacturers can establish more reliable endotoxin detection protocols for biologic drug products.
To learn more about how Fujifilm and Predictive Oncology’s endotoxin offerings could benefit your drug formulation efforts, we invite you to watch the replay of our webinar here.
Interested in learning more?
We want to hear about your drug development challenges—and identify ways to solve them together. Complete the form to get in touch with our team of experts from Predictive Oncology and Fujifilm.